Warwick CordenLloyd - Psyence Biomedical Chief Officer
| PBM Stock | USD 3.51 0.17 5.09% |
Executive
Warwick CordenLloyd is Chief Officer of Psyence Biomedical Ltd
| Age | 44 |
| Address | 121 Richmond Street West, Toronto, ON, Canada, M5H2K1 |
| Phone | 416-346-7764 |
| Web | https://www.psyencebiomed.com |
Psyence Biomedical Management Efficiency
The company has Return on Asset of (1.2635) % which means that on every $100 spent on assets, it lost $1.2635. This is way below average. Psyence Biomedical's management efficiency ratios could be used to measure how well Psyence Biomedical manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Psyence Biomedical's Return On Capital Employed is very stable compared to the past year. As of the 29th of November 2024, Return On Equity is likely to grow to 4.90, though Return On Tangible Assets are likely to grow to (42.93). At this time, Psyence Biomedical's Total Current Assets are very stable compared to the past year. Non Currrent Assets Other is expected to grow at the current pace this year, while Total Assets are likely to drop about 1.1 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Carlos Bais | Inhibrx | N/A | |
| Charbel PharmD | Inhibrx | N/A | |
| MD MBA | Molecular Partners AG | N/A | |
| Daniel Steiner | Molecular Partners AG | N/A | |
| MD MBA | Eliem Therapeutics | 50 | |
| Josep Garcia | Inhibrx | N/A | |
| Pamela Trail | Molecular Partners AG | 68 | |
| Matteo MD | Cue Biopharma | 55 | |
| Valerie Morisset | Eliem Therapeutics | 54 | |
| Dr Esq | Enliven Therapeutics | 47 | |
| Lucinda Warren | Cue Biopharma | N/A | |
| Ashraf Amanullah | Inhibrx | 56 | |
| Anne DVM | Molecular Partners AG | N/A | |
| David MBA | Inhibrx | N/A | |
| KerriAnn Millar | Cue Biopharma | 54 | |
| Zamaneh MD | Tff Pharmaceuticals | 60 | |
| Emily Pimblett | Eliem Therapeutics | 40 | |
| Bonne MBA | Inhibrx | 47 | |
| Helen MD | Enliven Therapeutics | 61 | |
| Brendan Eckelman | Inhibrx | 45 | |
| Nishi MD | Eliem Therapeutics | N/A | |
Management Performance
| Return On Asset | -1.26 |
Psyence Biomedical Leadership Team
Elected by the shareholders, the Psyence Biomedical's board of directors comprises two types of representatives: Psyence Biomedical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Psyence. The board's role is to monitor Psyence Biomedical's management team and ensure that shareholders' interests are well served. Psyence Biomedical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Psyence Biomedical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Taryn Vos, General Counsel | ||
| Jody Aufrichtig, Executive CoFounder | ||
| Neil MD, CEO Director | ||
| Tony Budden, Chief Officer | ||
| MaryElizabeth Gifford, Executive Impact | ||
| Warwick CordenLloyd, Chief Officer |
Psyence Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Psyence Biomedical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -1.26 | ||||
| Current Valuation | 12.32 M | ||||
| Shares Outstanding | 16.7 M | ||||
| Shares Owned By Insiders | 58.48 % | ||||
| Shares Owned By Institutions | 13.24 % | ||||
| Number Of Shares Shorted | 823.87 K | ||||
| EBITDA | (2.75 M) | ||||
| Net Income | (51.16 M) | ||||
| Cash And Equivalents | 281.63 K | ||||
| Cash Per Share | 0.02 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Psyence Biomedical Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Psyence Biomedical. If investors know Psyence will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Psyence Biomedical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (7.82) | Return On Assets (1.26) |
The market value of Psyence Biomedical is measured differently than its book value, which is the value of Psyence that is recorded on the company's balance sheet. Investors also form their own opinion of Psyence Biomedical's value that differs from its market value or its book value, called intrinsic value, which is Psyence Biomedical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Psyence Biomedical's market value can be influenced by many factors that don't directly affect Psyence Biomedical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Psyence Biomedical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Psyence Biomedical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Psyence Biomedical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.